DiaMedica Therapeutics Inc (DMAC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DiaMedica Therapeutics Inc (DMAC) has a cash flow conversion efficiency ratio of -0.192x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.08 Million) by net assets ($47.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See DiaMedica Therapeutics Inc balance sheet quality to measure how much of total assets are equity-financed.
DiaMedica Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how DiaMedica Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check DMAC capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
DiaMedica Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DiaMedica Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alucon Public Company Limited
BK:ALUCON
|
0.018x |
|
F-SECURE OYJ
HE:FSECURE
|
0.148x |
|
Everspin Technologies Inc
NASDAQ:MRAM
|
0.008x |
|
Bangkok Land Public Company Limited
BK:BLAND
|
0.003x |
|
Altshuler Shaham Financial LTD
TA:ALTF
|
0.052x |
|
Gladstone Land Corporation
NASDAQ:LAND
|
0.016x |
|
Zhejiang Dibay Electric Co Ltd
SHG:603320
|
0.023x |
|
Akebia Ther
NASDAQ:AKBA
|
0.955x |
Annual Cash Flow Conversion Efficiency for DiaMedica Therapeutics Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of DiaMedica Therapeutics Inc from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see DiaMedica Therapeutics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $56.11 Million | $-29.06 Million | -0.518x | +4.47% |
| 2024-12-31 | $40.72 Million | $-22.08 Million | -0.542x | -47.81% |
| 2023-12-31 | $51.06 Million | $-18.73 Million | -0.367x | -1.42% |
| 2022-12-31 | $31.83 Million | $-11.51 Million | -0.362x | -29.96% |
| 2021-12-31 | $44.02 Million | $-12.25 Million | -0.278x | +21.18% |
| 2020-12-31 | $26.01 Million | $-9.19 Million | -0.353x | +70.45% |
| 2019-12-31 | $7.62 Million | $-9.10 Million | -1.195x | -257.17% |
| 2018-12-31 | $17.02 Million | $-5.70 Million | -0.335x | +93.15% |
| 2017-12-31 | $799.00K | $-3.90 Million | -4.881x | -101.17% |
| 2016-12-31 | $1.25 Million | $-3.02 Million | -2.426x | -318.40% |
| 2015-12-31 | $-1.23 Million | $-1.37 Million | 1.111x | -54.77% |
| 2014-12-31 | $-1.53 Million | $-3.76 Million | 2.456x | +161.68% |
| 2013-12-31 | $1.38 Million | $-5.50 Million | -3.983x | -64.48% |
| 2012-12-31 | $2.26 Million | $-5.48 Million | -2.421x | -320.16% |
| 2011-12-31 | $5.96 Million | $-3.44 Million | -0.576x | -106.67% |
| 2010-12-31 | $8.52 Million | $-2.38 Million | -0.279x | +86.39% |
| 2009-12-31 | $1.05 Million | $-2.15 Million | -2.049x | -288.44% |
| 2008-12-31 | $2.78 Million | $-1.47 Million | -0.528x | -76.73% |
| 2007-12-31 | $4.06 Million | $-1.21 Million | -0.299x | +75.65% |
| 2006-12-31 | $653.60K | $-801.16K | -1.226x | +25.36% |
| 2005-12-31 | $506.11K | $-831.17K | -1.642x | -1852.50% |
| 2004-12-31 | $-1.06 Million | $-99.35K | 0.094x | -- |
About DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal… Read more